Small cell lung cancer: Current therapy and promising new regimens

Oncologist

Volumn 7, Issue 3, 2002, Pages 234-238

  Okuno, Scott H ^a   Jett, James R ^a  

^a MAYO CLINIC   (United States)

Author keywords

Chemotherapy; Lung cancer; Radiation; Small cell

Indexed keywords

CARBOPLATIN; CISPLATIN; CYCLOPHOSPHAMIDE; DOXORUBICIN; ETOPOSIDE; GRANULOCYTE COLONY STIMULATING FACTOR; IFOSFAMIDE; IRINOTECAN; NAVELBINE; PACLITAXEL; TOPOTECAN; VINCRISTINE;

BONE MARROW SUPPRESSION; CANCER COMBINATION CHEMOTHERAPY; CANCER RADIOTHERAPY; CANCER STAGING; CANCER SURVIVAL; CLINICAL TRIAL; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; HUMAN; LUNG SMALL CELL CANCER; OUTCOMES RESEARCH; PRIORITY JOURNAL; REVIEW; SURVIVAL TIME;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARCINOMA, SMALL CELL; COMBINED MODALITY THERAPY; CRANIAL IRRADIATION; HUMANS; LUNG NEOPLASMS; NEOPLASM STAGING; SALVAGE THERAPY;

EID: 0036075894     PISSN: 10837159     EISSN: None     Source Type: Journal    
DOI: 10.1634/theoncologist.7-3-234     Document Type: Review

References (39)

1. Secular trends in histologic types of lung cancer
2. Clinical biology of small cell carcinoma: Relationship to surgical therapy
3. Lung cancer
4. TNM supplement
5. A randomized comparison of high-dose versus conventional-dose cyclophosphamide, doxorubicin, and vincristine for extensive-stage small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
6. Prospective randomized comparison of high-dose and standard-dose etoposide and cisplatin chemotherapy in patients with extensive-stage small cell lung cancer
7. Superiority of alternating non-cross-resistant chemotherapy in extensive small cell lung cancer. A multicenter, randomized clinical trial by the National Cancer Institute of Canada
8. Randomized study of cyclophosphamide, doxorubicin, and vincristine versus etoposide and cisplatin versus alteration of these two regimens in extensive small cell lung cancer: A phase III trial of the Southeastern Cancer Study Group
9. Maintenance chemotherapy in small-cell lung cancer: Long-term results of a randomized trial
10. Duration of chemotherapy in small cell lung cancer: A cancer research campaign trial
11. A meta-analysis of thoracic radiotherapy for small cell lung cancer
12. Twice-daily compared with once-daily thoracic radiotherapy in limited small cell lung cancer treated concurrently with cisplatin and etoposide
13. Phase III comparison of twice-daily split-course irradiation versus once-daily irradiation for patients with limited stage small cell lung carcinoma
14. Small cell lung cancer
15. Etoposide (VP-16) and cisplatin: An effective treatment for relapse in small-cell lung cancer
16. Randomized trial of cyclophosphamide, doxorubicin, and vincristine versus cisplatin and etoposide versus alternation of these regimens in small cell lung cancer
17. Phase II study of paclitaxel in patients with extensive-disease small cell lung cancer: An Eastern Cooperative Oncology Group study
18. Paclitaxel and G-CSF in previously untreated patients with extensive stage small cell lung cancer: A phase II study of the North Central Cancer Treatment Group
19. Phase II study of topotecan in patients with extensive-stage small cell carcinoma of the lung: An Eastern Cooperative Oncology Group trial
20. Randomized phase III study of irinotecan (CPT-11) and cisplatin versus etoposide and cisplatin in extensive disease small cell lung cancer: Japan Clinical Oncology Group study 9511
21. Topotecan and paclitaxel, an active couplet in untreated extensive disease small cell lung cancer
22. Paclitaxel plus topotecan plus G-CSF for previously untreated extensive small cell lung cancer: Preliminary analysis of CALGB 9430
23. Phase II trial of topotecan and paclitaxel with G-CSF support alternating with etoposide and cisplatin in previously untreated extensive stage small cell lung cancer
24. Topotecan vs observation following cisplatin plus etoposide in extensive-stage small cell lung cancer (E7593): A phase III trial of ECOG
25. Risk of brain metastasis from small cell carcinoma of the lung related to length of survival and prophylactic irradiation
26. Prophylactic cranial irradiation in small cell lung cancer: An update
27. Neurologic, neuropsychologic, and computed cranial tomography scan abnormalities in 2- to 10-year survivors of small cell lung cancer
28. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission
29. Prophylactic cranial irradiation for patients with small cell lung cancer in complete remission
30. Prophylactic cranial irradiation is indicated following complete response to induction therapy in small cell lung cancer: Results of a multicenter randomised trial
31. Topotecan, a new active drug in second-line treatment of small cell lung cancer: A phase II study in patients with refractory and sensitive disease
32. Topotecan versus cyclophosphamide, doxorubicin, and vincristine for the treatment of recurrent small-cell lung cancer
33. Phase II study of irinotecan (CPT-11) in patients with previously treated small-cell lung cancer (SCLC)
34. Activity of docetaxel (Taxotere) in small cell lung cancer
35. A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
36. Phase II study of vinorelbine (Navelbine) in previously treated small cell lung cancer patients
37. Carboplatin as second line treatment for recurrent or progressive brain metastases from small cell lung cancer
38. Treatment of patients with small-cell lung cancer refractory to etoposide and cisplatin with the topoisomerase I poison topotecan
39. Outcome of patients with small cell lung cancer during 20 years of clinical research at the US National Cancer Institute